Real-World Study of Locoregional Therapy with Bevacizumab and PD1L1 Inhibitors for Advanced Liver Cancer

What this Trial Is About

Researchers are exploring the effectiveness and safety of combining locoregional therapy with Bevacizumab and PD1L1 inhibitors in patients with advanced hepatocellular carcinoma who cannot undergo radical therapy. This observational, real-world study aims to collect clinical data to help answer important questions about managing this treatment approach in advanced liver cancer. The study is sponsored by Sun Yat-sen University and focuses on patients with stage B or C hepatocellular carcinoma. The treatments studied include locoregional therapies such as transarterial chemoembolization TACE or hepatic arterial infusion chemotherapy HAIC combined with intravenous Bevacizumab and various PD1L1 inhibitors, including Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, and Camrelizumab. Bevacizumab is given every three weeks at doses of 7.5 or 15 mgkg, while PD1L1 inhibitors are administered intravenously every three weeks at specified doses. This study gathers data from patients receiving these combined therapies as standard care. Participants will be monitored over time with assessments including progression-free survival at 12 months as the primary outcome. Secondary outcomes include overall survival, objective response rates, and adverse events up to 24 months. Clinical parameters, imaging, and laboratory tests are used to evaluate treatment effects and safety. This study will help provide real-world evidence on the management of advanced hepatocellular carcinoma using these combined therapies.

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma